Buradasınız

Anasayfa » Content

Tip 2 Diyabet Tedavisinde Son Gelişmeler

RECENT ADVANCES IN THE MANAGEMENT OF TYPE 2 DIABETES MELLITUS

Journal Name:

  • Türkiye Aile Hekimliği Dergisi

Publication Year:

  • 2007

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
Choices have increased in the treatment of type 2 diabetes with new antidiabetics and insulins. According to the new American Diabetes Association criteria, the goal in fasting glucose is <100mg/dl and 2 hours after meals it is <140mg/dl. The drugs which can be used for oral therapy in Type 2 diabetes are sul-phonilureas, non-sulphonilurea secretagogs, biguanides, alpha-glucosidase inhibitors and thiazolidinedions. The situations where insulin therapy is required are severe hypoglycemia, impaired glucose control with maximum dose of oral therapy, intervening dis¬eases (myocardial infarction, infection) or operation, pregnancy, kidney disease, liver disease, allergy or intolerance to oral antidia-betics. Mixed insulins (NPH, Human analog), rapid acting insulin analogues (Lispro, aspart) and basal insulin analogues (insulin glargine) can also be used.
Bookmark/Search this post with
Abstract (Original Language): 
Son yıllarda çıkan yeni oral antidiyabetikler ve insülinlerle tip 2 diyabet tedavisinde seçenekler çoğalmıştır. Amerikan Diyabet Der-neği'nin yeni ölçütlerine göre hedefler açlık kan şekeri <100mg/dl, yemekten sonra 2.saatte <140mg/dl olarak belirlenmiştir. Tip 2 diyabetin oral tedavisinde kullanılan ilaçlar sülfonilü-reler, sulfonilüre olmayan insülin sekretagoglar, biguanidler, alfa-glikozidaz inhibitörleri ve tiazolidinedionlardır. insülin tedavisi ge¬rektiren durumlar ise ağır hipoglisemi, oral ilaçların maksimum dozlarını alırken bozuk glikoz kontrolü, araya giren hastalıklar (miyokard infarktüsü, enfeksiyon) veya operasyon, gebelik, böbrek hastalığı, karaciğer hastalığı, oral antidiyabetiklere intolerans veya alerjidir. Karışık insülinler (NPH, human analog), çabuk etkili insülin analogları (lispro insülin, aspart insülin) ve bazal insülin analogları (insülin glargin) kullanılabilir.
FULL TEXT (PDF): 
PDF icon arastrmx_116859_11_pp_43-47.pdf
  • 1
43-47
  • Turkish

REFERENCES

References: 

1. Eriksson J, Fransilla-Kallunki A, Ekstrand A ve ark. Early metabolic defects in persons at increased risk for non-insulin-dependent diabetes melli-tus. N Engl J Med 1989; 321: 337-43.
2. Warram JH, Martin BC, Krowlewski AS Soeldner JS, Kahn CR. Slow glucose removal rate and hyperinsulinemia precede the development of type II diabetes in the offspring of diabetic patients. Ann Intern Med 1990; 113: 909-15.
3. DeFronzo RA, Ferrannini E, Simonson DC. Fasting hyperglycemia in non-insulin-dependent diabetes mellitus: contributions of excessive hepatic glu¬cose production and impaired tissue glucose production and impaired tissue glucose uptake. Metabolism 1989; 38: 387-95.
4. Nesher R, Della Casa L, Litvin Y ve ark. Insulin deficiency and insulin resistance in type 2 (non-insulin-dependent) diabetes: quantitative contributions of pancreatic and peripheral responses to glucose homeostasis. Eur J Clin Invest 1987; 17(3): 266-74.
5. The effect of intensive treatment of diabetes on the development and pro¬gression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. NEngl J Med
1993; 329: 977-86.
6. Shichiri M, Kishikawa H, Ohkubo Y, Wake N. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 2000; 23(supp 2): B21-9.
7. Stratton IM, Adler AI, Matthews DR ve ark. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: 405-12.
8. International Diabetes Federation. Global Guideline for Type 2 Diabetes,
2005.
9. Keyserling TC, Samuel-Hodge CD, Ammeznan AS ve ark. A randomized trial of an intervention to improve self-care behavors of African-American women with type 2 diabetes: impact on physical activity. Diabetes Care
2002; 25: 1576-83.
10. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2
diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.
Lancet 1998; 352: 837-53.
11. Rosenstock J, Samols E, Muchmore DB, Windfeld K. Glimepiride, a new once-daily sulfonylurea: a double-blind placebo-controlled study of NIDDM patients. Glimepiride Study Group. Diabetes Care 1996; 19: 1194-9.
12. Prof. Dr.
Uğu
r Görpe. Oral Antidiyabetik tedavi- Cerrahpaşa Tıp Fakültesi Sürekli Tıp Eğitimi Sempozyum Dizisi No: 4; 1997; 93-95.
13. Damsbo P, Clauson P, Marbury TC, Windfeld K. A double-blind ran¬domized comparison of meal-related glycemic control by repaglinide and gly-buride in well-controlled type 2 diabetic patients. Diabetes Care 1999; 22(5):
789-94.
14. Inzucchi SE, Maggs DG, Spollett GR ve ark. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J
Med 1998; 338: 867-72.
15. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352 :854-65.
16. Caniff RF, Shapiro JA, Robbins D ve ark. Reduction of glycosylated hemoglobin and postprandial hyperglycemia by acarbose in patients with NIDDM: placebo-controlled dose-comparison study. Diabetes Care 1995; 8:
817-24.
17. Balfour JA, Mc Tavish D. Acarbose: an update of its pharmacology and therapeutic use in diabetes mellitus. Drugs 1993; 46: 1025-54.
18. Mayerson AB, Inzucchi SE. Type 2 diabetes therapy. A pathophysiological-ly based approach. Postgraduate Medicine 2002; 111: 1-12.
19. Mathisen A, Geerlof J, House V. The effect of pioglitazone on glucose con¬trol and lipid profile in patients with type 2 diabetes. Diabetes 1999; 48(Suppl
1): A102-3.
20. Nolan JJ, Jones NP, Pathwardhan R, LF Deacon. Rosiglitazone taken once daily provides effective glycemic control in patients with type 2 diabetes
mellitus. Diabetic Med 2000; 17: 287-94.
21. Parulkar AA, Pendergrass ML, Granda-Ayola R, Lee TR, Fonseca VA.
Nonhypoglycemic effects of thiazolidinediones. Ann Intern Med 2001; 134:
61-71.
22. Coppan R. The Changing model of insulin use in type 2 diabetes: techniques,
tactics for getting to goal. Postgrad Med 2003; 113: 59-64.
23. Simonson Dc, Kaurides IA, Feinglos M,Shamoon H, Fischette CT.
Efficacy, safety and dose-response characteristics of glipizide gastrointestinal therapeutic system on glycemic control and insulin secretion in NIDDM. Results of the two multicenter, randomized, placebo- controlled clinical trials. The glipizide gastrointestinal therapeutic system study group. Diabetes Care
1997; 20: 597-606.
24. YKI- Jarvinen H. The proactive study: some answers, many questions. The
Lancet 2005; 366: 1241-2.
25. Choe HM, Mitrovich S, Dubay D, Hayward RA, Krein SL, Vijan S.
Proactive case management of high-risk patients with Type 2 Diabetes Mellitus by a clinical Pharmacist: A randomized controlled trial. The
American Journal of Managed Care 2005; 11: 253-60.
26. Fourlanos J, Perry C, Stein MS, Stankovich J, Harrisou LC, Colman PG.
A clinical screening tool identifies autoimmune diabetes in adults. Diabetes
Care 2006; 29: 970-5.
27. Scheen AJ, Lefebvre PJ. Proactive study: secondary cardiovascular preven¬tion with pioglitazone in type 2 diabetic patients. Rev Med Liege 2005; 60:
896-901.
28. Dormandy JA, Charbonnel B, Eckland DJ ve ark. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitazone Clinical trial in Macrovascular Events): a
randomised controlled trial. Lancet 2006; 25; 367(9515): 982.
29. White Jr JR, Campbell K, Hirsch IB. Novel insulins and strict glycemic control. Analogues approximate normal insulin secretory response. Postgrad
Med 2003; 113: 30-6
30. Campbell RK, White JR. Insulin therapy in type 2 diabetes. J Am Pharm Assoc (Wash) 2002; 42: 602-11.
31. Bohannon NJV. Optimizing insulin regimens in type 1 diabetes. How to help patients get control of their life. Postgrad Med 2003; 113: 39-42
32. Levien TL, Baker DE, White JR, Campbell RK. Insulin glargine: a new basal insulin. Ann Pharmacother 2002; 36: 1019-27.
33. Vague P, Selam JL, Skeie S ve ark. Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type1 diabetes on a basal-bolus regimen with premeal insulin aspart. Diabetes Care 2003; 26:590-6.

Thank you for copying data from http://www.arastirmax.com